In patients with venous thromboembolism (VTE), the influence on outcome of using direct
oral anticoagulants (DOACs) at non-recommended doses or regimens (once vs twice daily) …

Background: In patients with venous thromboembolism (VTE), the study of the case fatality
rate (CFR) of VTE recurrences and bleeding complications may be of help to balance the …

Introduction Randomized controlled trials have shown that direct oral anticoagulants
(DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the …

We assessed the real‐life use of direct oral anticoagulants (DOACs) in patients with venous
thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016 …

Abstract Background Direct oral anticoagulants (DOACs), namely rivaroxaban, apixaban,
dabigatran, and edoxaban, are now included together with warfarin as standards of care for …

Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep
vein thrombosis (DVT) are considered expressions of the same disease, termed as venous …

Direct oral anticoagulants (DOACs) are rapidly replacing vitamin K antagonists (VKAs) for
treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
For decades, low molecular weight heparins (LMWH) and vitamin K-antagonists have been …

Importance Extending the duration of oral anticoagulation for venous thromboembolism
(VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear …

Introduction The frequency and case fatality of venous thromboembolism (VTE) and major
bleeding during the initial 3 months of therapy in those treated for symptomatic VTE with …